TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00658840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine (Xeloda®)
Description: Capecitabine is administered orally at a dose of 800 mg/m2 twice daily (total daily dose 1600mg/ m2) continuous regimen regimen during RT (5 days of treatment followed by a 2 day rest: Saturday and Sunday). Capecitabine is given approximately 12 hours apart and taken orally with water within 30 minutes after ingestion of food (breakfast or dinner).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Localization, simulation and immobilization
Description: Radiation dose and planning~1. Total dose 55.8Gy, 28 fractions, 6-7 weeks (1.8 Gy/day). A cone down after 45 Gy will be performed to emcompass GTV with a margin of 1-1.5cm.~2. Dose prescription : 90% isodose volume of prescribed dose encompassed PTV~3. The dose-volume histogram (DVH) of targets, such as GTV, CTV, and PTV, and the normal tissues, such as the liver, duodenum, stomach, the kidneys, spinal cord, etc., was calculated.
Study: NCT02037256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Undergo autologous hematopoietic stem cell transplantation
Study: NCT02945254

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIghtingale (R) device for filtered white noise (Cambridge Sound Management, Waltham, MA)
Study: NCT03396536

Intervention type: OTHER
Intervention: Evaluation of KM
Description: KM will be evaluated. The alveolar mucosa will be stained with Lugol's solution, by means of a cotton swab. A cotton roll will be soaked in the solution and gently applied on the mucosa around the implant. Since Lugol's solution is selective to the glycogen present in AM, the muco-gingival junction as the borderline between the blue-stained alveolar mucosa and KM can be easily identified.~A manual periodontal probe with 1 mm markings will measure the distance from the peri-implant margin and the muco-gingival junction.~Mucosal thickness (MT) will be measured after topical application of the anesthetics. MT will be evaluated inserting a 27G needle with a rubber stop 1 mm below the peri-implant mucosal margin at the mid-buccal aspect, until the abutment is engaged. The needle will be removed and the distance between the rubber stop and the point of the needle will be measured with a manual periodontal probe.
Study: NCT02847026

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IPV at 14 and 22 weeks of age, Rotarix
Description: Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 14 weeks of age and a full dose IPV booster at 22 weeks of age. They will also receive the rotavirus vaccine, Rotarix, at 6 and 10 weeks of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IPV at 14 and 22 weeks of age, RotaTeq
Description: Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 14 weeks of age and a full dose IPV booster at 22 weeks of age. They will also receive the rotavirus vaccine, RotaTeq, at 6, 10, and 14 weeks of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IPV at 14 and fIPV at 22 weeks, Rotarix
Description: Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 14 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. They will also receive the rotavirus vaccine, Rotarix, at 6 and 10 weeks of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IPV at 14 and fIPV at 22 weeks, RotaTeq
Description: Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 14 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. They will also receive the rotavirus vaccine, RotaTeq, at 6, 10, and 14 weeks of age.
Study: NCT01341639

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RotaTeq
Description: RotaTeq (pentavalent combination live vaccine of 5 human-bovine reassortant rotavirus strains) 2 mL oral dose at 2, 3, and 4 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar 13
Description: Prevenar 13 0.5 mL intramuscular injection at 2, 3, 4,and 13 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar 13
Description: Prevenar 13 0.5 mL intramuscular injection at 2, 3, 4,and 13 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ProQuad™
Description: ProQuad™ 0.5 mL subcutaneous injection at 12 and 13 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ProQuad™
Description: ProQuad™ 0.5 mL subcutaneous injection at 12 and 13 months of age
Study: NCT00795561

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Day care
Description: Patients randomised to day care treatment of NVP will be instructed to present to the day services unit where they will receive a pre-agreed fluid and anti emetic regimen.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient
Description: Patients randomised to inpatient management of NVP will be admitted to hospital where they will receive a pre-agreed fluid and anti emetic regimen.
Study: NCT00406757

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nelarabine injection 400mg/m2
Description: Cycle 1: Nelarabine 400mg/m2 will be administered once a day from Day 1 to Day 5.~Cycle 2 and subsequent Cycles: Nelarabine 650mg/m2 will be administered once daily from Day 1 to DAy 5.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nelarabine injection 650mg/m2
Description: Nelarabine 650mg/m2 will be administered once a day from Day 1 to Day 5.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nelarabine injection 650mg/m2
Description: Nelarabine 650mg/m2 will be administered once a day from Day 1 to Day 5.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nelarabine injection 1000mg/m2
Description: Cycle 1: Nelarabine 1000mg/m2 will be administered once a day on Days 1, 3 and 5.~Cycle 2 and subsequent Cycles: Nelarabine 1500mg/m2 will be administered once a day on Days 1, 3 and 5.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nelarabine injection 1500mg/m2
Description: Nelarabine 1500mg/m2 will be administered once a day on Days 1, 3 and 5.
Study: NCT01058161

Intervention type: OTHER
Group type: OTHER
Intervention: high-field MRI (3 Teslas)
Description: high-field MRI (3 Teslas)

Intervention type: OTHER
Group type: OTHER
Intervention: high-field MRI (3 Teslas)
Description: high-field MRI (3 Teslas)

Intervention type: OTHER
Group type: OTHER
Intervention: high-field MRI (3 Teslas)
Description: high-field MRI (3 Teslas)

Intervention type: OTHER
Group type: OTHER
Intervention: high-field MRI (3 Teslas)
Description: high-field MRI (3 Teslas)

Intervention type: OTHER
Group type: OTHER
Intervention: high-field MRI (3 Teslas)
Description: high-field MRI (3 Teslas)

Intervention type: OTHER
Group type: OTHER
Intervention: high-field MRI (3 Teslas)
Description: high-field MRI (3 Teslas)

Intervention type: OTHER
Group type: OTHER
Intervention: high-field MRI (3 Teslas)
Description: high-field MRI (3 Teslas)

Intervention type: OTHER
Group type: OTHER
Intervention: high-field MRI (3 Teslas)
Description: high-field MRI (3 Teslas)

Intervention type: OTHER
Group type: OTHER
Intervention: high-field MRI (3 Teslas)
Description: high-field MRI (3 Teslas)
Study: NCT01853306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: veliparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: veliparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: veliparib
Study: NCT04125628

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise with cooling
Description: The exercise training session involved head cooling and neck wraps. Participants followed a 40-minute continuous cycling where they performed an incremental sub-maximal exercise protocol beginning at 45 W, increasing 10 W every 10 min for a total of four stages on a semirecumbent cycle ergometer in a 20oC room. Before and after the completion of the condition each participant performed a variety of functional ability tests. The evaluation of the core temperature and the assessment of the patient's quality of life also was performed

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise without cooling
Description: The exercise session performed without cooling. Participants followed a 40-minute continuous cycling where they performed an incremental sub-maximal exercise protocol beginning at 45 W, increasing 10 W every 10 min for a total of four stages on a semirecumbent cycle ergometer in a 20oC room. Before and after the completion of the session each participant performed a variety of functional ability tests. The evaluation of the core temperature and the assessment of the patient's quality of life also was performed.
Study: NCT01336894

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic conventional surgery
Description: Undergo surgery

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: iodine I 125
Description: Undergo seed implant radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: Undergo radiotherapy
Study: NCT01352702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: Patients assigned to this group will receive Dabigatran

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenprocoumon
Description: Patients assigned to this group will receive Phenprocoumon
Study: NCT01273532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tapentadol (CG5503) ER 100-mg TRF
Description: 100mg TRF single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tapentadol (CG5503) ER 50-mg TRF
Description: 100 mg TRF single oral dose
Study: NCT05039034

Intervention type: OTHER
Intervention: Advice according to primary prevention guidelines on stroke of China

Intervention type: OTHER
Intervention: Advice according to primary prevention guidelines on stroke of China

Intervention type: OTHER
Intervention: Advice according to primary prevention guidelines on stroke of China
Study: NCT02312674

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement
Description: Beginning with the start of palliative therapy, depending on the nutritional status, one, two, or three cans per day are ingested during a period of three months.
Study: NCT02171182

Intervention type: DRUG
Intervention: Qutenza
Description: capsaicin patch
Study: NCT00566358

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Duodenal exclusion surgery
Description: Under open laparotomy, a duodenum section 2cm below the pylorus and a jejunum section below Treitz's Angle to create an excluded biliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the gastrojejunal continuity and the anastomosis of the excluded biliopancreatic limb is done 100cm below the jejunal-pyloric union.
Study: NCT02513992

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intra-arterial injection of tracer
Description: intra-arterial ictal injection of perfusion tracer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99m-Technetium Ethyl Cysteinate Dimer
Description: administration of perfusion tracer 99m Tc-ECD during epileptic seizure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intra-arterial catheter
Description: placement of intra-arterial catheter via femoral artery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pressure injector
Description: the injection of the perfusion tracer will be delivered with a pressure injector
Study: NCT03115008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-based terminal feedback
Description: Terminal feedback is given after skill performance using video-based coaching coupled with a validated polypectomy assessment tool
Study: NCT04478227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Nplate is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Nplate is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
Study: NCT01133860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag
Description: Eltrombopag, administered orally, 50 mg/daily for 21 days. Patients with platelet counts between 100 and 150x10e9/L at day 21 will continue eltrombopag 50 mg/daily for 21 additional days. Patients with platelet count lower than 100x10e9/L at day 21 will receive eltrombopag 75 mg/daily for additional 21 days. Patients with more than 150x10e9 platelets/L at day 21 will stop therapy.
Study: NCT01500746

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulse lavage treatment
Description: A pulse lavage machine will be used to irrigate the wound with a total of 4 liters of water, twice daily, for a total of 4 days (8 treatments).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dressing changes
Description: Wounds will be treated with moist gauze dressing changes twice daily for a total of 4 days (8 treatments).
Study: NCT01079624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose-insulinotropic peptide, Glucagon-like peptide-1
Description: GIP 2 and 5 pmol/kg min GLP-1 0.7 pmol/kg min

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Glucose-insulinotropic peptide, Glucagon-like peptide-1
Description: GIP 2 and 5 pmol/kg min GLP-1 0.7 pmol/kg min
Study: NCT01622712

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rebound HRD Mesh
Description: Patients with unilateral inguinal hernia receive a nitinol containing large pore polypropylene mesh.
Study: NCT02334527

Intervention type: DRUG
Group type: OTHER
Intervention: Palbociclib
Description: 125 mg capsule will be taken once per day orally and continuously for 3 weeks followed by 1 week off.
Study: NCT01706965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kuvan
Description: 20mg/kg using a daily dosing schedule. To increase tolerability, treatment will be initiated at 10mg/kg for the first week of the study. Given the short length of the trial, no dose adjustments will be made for changes in weight

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin
Description: Multi-vitamin will be used as an active control in this study. Will be dosed daily
Study: NCT02538679

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The usual intraoperative and postoperative pain control; NO TAP block performed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: US TAP Bupivacaine/Epinephrine
Description: Ultrasound guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lap TAP Bupivacaine/Epinephrine
Description: Laparoscopic guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
Study: NCT04410328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care
Description: Participants in the experimental group will receive Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally (if they have a feeding tube), 2 times daily starting on the day of enrollment for a total of 2 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Participants will receive standard care starting on the day of enrollment for a total of 2 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Participants will receive standard care starting on the day of enrollment for a total of 2 weeks.
Study: NCT01563978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fostamatinib
Description: fostamatinib 100 mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT00324012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin, taxotere
Description: cisplatin 75 mg/m2 Taxotere 75 mg/m2
Study: NCT00660920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Comparison of different dosages of drug given orally once per day.
Study: NCT03698864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCS499
Description: PCS499 900mg twice a day with food
Study: NCT05085743

Intervention type: DIAGNOSTIC_TEST
Intervention: Deep convolutional neural networks analysis
Description: using Deep convolutional neural networks to analyze pre-intubation chest radiographs along with patients' data to predict the proper depth of ETT fixation

Intervention type: DIAGNOSTIC_TEST
Intervention: Deep convolutional neural networks analysis
Description: using Deep convolutional neural networks to analyze pre-intubation chest radiographs along with patients' data to predict the proper depth of ETT fixation
Study: NCT03133949

Intervention type: OTHER
Intervention: Establish the clinical, biological and radiological characteristics of patients
Description: Establish the clinical, biological and radiological characteristics of patients

Intervention type: OTHER
Intervention: Establish the clinical, biological and radiological characteristics of patients
Description: Establish the clinical, biological and radiological characteristics of patients
Study: NCT01717183

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urgo 310 3113
Description: URGO 310 3113 dressing may be changed every 2 to 4 days, and left in place for up to 7 days, depending on the level of exudate and the wound condition

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo URGO 310 3113 dressing
Study: NCT04533776

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Celiac Disease Definition, Symptoms and Treatment
Description: * Adolescents share their knowledge about the disease~* Emphasizing the definition and symptoms of celiac disease~* Discussion of the treatment of celıac disease Expression Question-Answer Discussion Summarizing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Difficulties Due to Celiac Disease
Description: * Determining what experience living with celiac is fot the patient (What do I think about the disease, how do I feel about the disease,how do I perceive the disease, how does the disease affect me)~* Determining the difficulties encountered in Daily life due to illness (How do I deal with difficulties)~* Determining how the disease affects life Expression Question-Answer Discussion Summarizing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gluten Free Diet in Celiac Disease
Description: * Evaluating dietary information~* Identifying the difficulties in diet therapy Expression Question-Answer Discussion Summarizing Case Study Presentation (Transfer of life experience of an individual who is 22 years old with celiac disease)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Difficulties Related to Disease in School and Social Life
Description: * Assessment of difficulties encountered in school and social life~* Evaluation of the solution suggestions fort he difficulties encountered Expression Question-Answer Discussion Summarizing Örnek Olay Sunumu (Transfer of life of experience of a 23 years old dietician with celiac disease)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Celiac Disease and Its Effects on Acamdemic Success Peer Relations
Description: * Evaluation of the effects of the disease on academic success~* Evaluation of the effects of the disease on peer relationships in the school enviroment~* Difficulties experienced in peer relations and evaluation of relationships (exclusion) Expression Question-Answer Discussion Summarizing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Celiac Diseae anf Future Goals
Description: * General summary of all sessions so far~* Summarizing the topics discussed in the previous session~* Evaluating the future goals of the participants Expression Question-Answer Discussion Summarizing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Intervention: routine health care- control group
Description: Peer interactive group support was not provided to the control group. After all the sessions of the peer interactive group support of the study were completed, a separate training meeting was held for the control group.
Study: NCT01647308

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ISIS-APOCIIIRX
Description: 3 doses of ISIS ISIS-APOCIIIRX on alternate days during the first week and then once-weekly doses for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 doses of placebo on alternate days during the first week and then once-weekly doses for 12 weeks.
Study: NCT03164915

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LIV-GAMMA SN Inj.
Study: NCT02155959

Intervention type: DEVICE
Intervention: toric intraocular lens
Description: toric intraocular lens
Study: NCT00859092

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Simply Thick
Description: Simply Thick® added to each bottle of formula or beast milk to create nectar or honey consistency
Study: NCT03116503

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnosis of bipolar disorder and comorbid depression
Description: Evaluation of the number of diagnosis of bipolar disorder and comorbid depression
Study: NCT01409421

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational interviewing
Description: counseling intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: three phone calls to remind patients to take their eye drops
Description: reminder phone calls
Study: NCT00216320

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WalkAide
Description: Arm 1 - Subjects wear WalkAide for 6 weeks then cross over to AFO wear for 6 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WalkAide
Description: Arm 1 - Subjects wear WalkAide for 6 weeks then cross over to AFO wear for 6 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AFO
Description: Arm 2 - Subjects wear AFO for 6 weeks then cross over to WalkAide wear for 6 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AFO
Description: Arm 2 - Subjects wear AFO for 6 weeks then cross over to WalkAide wear for 6 weeks

Intervention type: DEVICE
Group type: OTHER
Intervention: AFO
Description: Arm 3 - Subjects wear AFO for entire 12 weeks with no crossover